Shares of The J.M. Smucker Co. (NYSE: SJM) were down on Monday. The stock has gained 10% over the past 12 months. The company is set to report third quarter 2023 earnings results on Tuesday, February 28, before market open. Here’s what to expect from the earnings report:
Revenue
Analysts are projecting revenue of $2.22 billion for JM Smucker in Q3 2023. This compares to sales of $2.1 billion reported in the same period last year. In the second quarter of 2023, sales increased 8% year-over-year to $2.20 billion.
Earnings
Analysts are predicting EPS of $2.12 for Q3 2023 which compares to adjusted EPS of $2.33 in Q3 2022. In Q2 2023, the company reported adjusted EPS of $2.40, which was down 1% year-over-year.
Points to note
In the second quarter of 2023, SJM’s comparable sales increased 11%. The company continued to see strength in the pet, snacking and coffee categories. The Pet Foods segment recorded comparable net sales growth of 14% in Q2, with strength in categories like cat food, dog food and dog snacks.
Net sales in the Coffee segment increased 10% helped by strength in the at-home coffee portfolio. The at-home coffee category is expected to remain resilient despite declines in volume and impacts from inflation as the majority of coffee-drinking occasions occur at home.
The company’s strong brand portfolio will continue to be an advantage. In Q2, 71% of its US retail sales came from brands that are growing or maintaining share. The Consumer Foods business continues to benefit from strength in Uncrustables sandwiches and Smucker’s fruit spreads.
The ongoing cost inflation, supply chain volatility and macroeconomic headwinds continue to impact the company’s business and this is likely to have continued through the third quarter. Price increases might have had an effect on volumes as well. In addition, the Jif peanut butter recall will continue to impact results throughout this fiscal year.
Click here to read the full transcript of JM Smucker’s Q2 2023 earnings conference call
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
